Mary Rozenman

Board Director

Mary Rozenman brings more than 15 years of scientific expertise, company building, and transactions leadership in the biotech industry to Tessera’s Board of Directors. She serves as the CFO and CBO of insitro, leading strategic and operational finance and accounting strategy, business development, investor relations, corporate communications, as well as project and portfolio management.

Prior to insitro, Dr. Rozenman served as the Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she oversaw business development and partnerships with companies including Regeneron/Sanofi and Nestle Health Science and supported the company’s strategic finance and investor relations efforts. Across her time at both insitro and Aimmune, Dr. Rozenman has raised more than $1 billion in capital through a range of public and private transactions, including co-leadership of Aimmune’s IPO in 2015. Before Aimmune, Dr. Rozenman was a vice president at Longitude Capital, where she focused on biotechnology investments and participated in multiple therapeutics investments and boards of directors, including observing on Aimmune’s board. Mary was also previously a junior partner at McKinsey & Company, focused on pharmaceuticals and corporate finance.

She received her Ph.D. in Organic Chemistry and Chemical Biology from Harvard University and her B.A. in Biochemistry and Russian Literature from Columbia University. Her scientific work has been published in premier scientific journals, and she is a named inventor on several patents.